flucytosine has been researched along with HIV in 7 studies
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.
flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.
HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amphotericin B deoxycholate (AmBd) is the recommended induction treatment for HIV-associated cryptococcal meningitis (CM)." | 9.20 | Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. ( Bicanic, T; Bottomley, C; Brouwer, AE; Harrison, TS; Hosseinipour, MC; Jackson, A; Jarvis, JN; Limmathurotsakul, D; Loyse, A; Meintjes, G; Muzoora, C; Phulusa, J; Taseera, K; van der Horst, C; White, NJ; Wilson, D; Wood, R, 2015) |
| "The AmBisome Therapy Induction Optimization (AMBITION-cm) trial, conducted in eastern and southern Africa, showed that a single, high dose (10 mg/kg) of liposomal amphotericin B, given with an oral backbone of fluconazole and flucytosine, was noninferior to the World Health Organization (WHO)-recommended regimen of 7 days of amphotericin B deoxycholate plus flucytosine for treatment of human immunodeficiency virus (HIV)-associated cryptococcal meningitis and has been incorporated into WHO treatment guidelines." | 5.69 | How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis to High-Income Settings? ( Boulware, DR; Harrison, TS; Hosseinipour, MC; Jarvis, JN; Lawrence, DS; Lortholary, O; Meintjes, G; Mosepele, M; Mwandumba, HC, 2023) |
| "Amphotericin B deoxycholate (AmBd) is the recommended induction treatment for HIV-associated cryptococcal meningitis (CM)." | 5.20 | Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis. ( Bicanic, T; Bottomley, C; Brouwer, AE; Harrison, TS; Hosseinipour, MC; Jackson, A; Jarvis, JN; Limmathurotsakul, D; Loyse, A; Meintjes, G; Muzoora, C; Phulusa, J; Taseera, K; van der Horst, C; White, NJ; Wilson, D; Wood, R, 2015) |
| "HIV-uninfected CM patients who received high-dose fluconazole (800 mg/d) for initial therapy in Huashan Hospital were included in this retrospective study from January 2013 to December 2018." | 4.31 | Induction therapy with high-dose fluconazole plus flucytosine for human immunodeficiency virus-uninfected cryptococcal meningitis patients: Feasible or not? ( Cheng, JH; Jiang, YK; Luo, Y; Wang, X; Zhao, HZ; Zhou, LH; Zhu, LP; Zhu, RS, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, HZ | 1 |
| Cheng, JH | 1 |
| Zhou, LH | 1 |
| Luo, Y | 1 |
| Zhu, RS | 1 |
| Jiang, YK | 1 |
| Wang, X | 1 |
| Zhu, LP | 1 |
| Harrison, TS | 2 |
| Lawrence, DS | 1 |
| Mwandumba, HC | 1 |
| Boulware, DR | 1 |
| Hosseinipour, MC | 2 |
| Lortholary, O | 1 |
| Meintjes, G | 2 |
| Mosepele, M | 1 |
| Jarvis, JN | 2 |
| Bicanic, T | 1 |
| Bottomley, C | 1 |
| Loyse, A | 1 |
| Brouwer, AE | 1 |
| Muzoora, C | 1 |
| Taseera, K | 1 |
| Jackson, A | 1 |
| Phulusa, J | 1 |
| van der Horst, C | 1 |
| Limmathurotsakul, D | 1 |
| White, NJ | 1 |
| Wilson, D | 1 |
| Wood, R | 1 |
| Liao, CH | 1 |
| Chi, CY | 1 |
| Wang, YJ | 1 |
| Tseng, SW | 1 |
| Chou, CH | 1 |
| Ho, CM | 1 |
| Lin, PC | 1 |
| Ho, MW | 1 |
| Wang, JH | 1 |
| Du, J | 1 |
| Surzhykov, S | 1 |
| Lin, JS | 1 |
| Newton, MG | 1 |
| Cheng, YC | 1 |
| Schinazi, RF | 1 |
| Chu, CK | 1 |
| Powderly, WG | 1 |
| Griffon, JF | 1 |
| Mathé, C | 1 |
| Faraj, A | 1 |
| Aubertin, AM | 1 |
| De Clercq, E | 1 |
| Balzarini, J | 1 |
| Sommadossi, JP | 1 |
| Gosselin, G | 1 |
1 review available for flucytosine and HIV
| Article | Year |
|---|---|
Current approach to the acute management of cryptococcal infections.
Topics: AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; CD4 Lymphocyte Count; Cryp | 2000 |
2 trials available for flucytosine and HIV
| Article | Year |
|---|---|
How Applicable Is the Single-Dose AMBITION Regimen for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis to High-Income Settings?
Topics: Antifungal Agents; Drug Therapy, Combination; Fluconazole; Flucytosine; HIV; HIV Infections; Humans; | 2023 |
Toxicity of Amphotericin B Deoxycholate-Based Induction Therapy in Patients with HIV-Associated Cryptococcal Meningitis.
Topics: Adult; Amphotericin B; Anemia; Antifungal Agents; Blood Cell Count; Coinfection; Creatinine; Cryptoc | 2015 |
4 other studies available for flucytosine and HIV
| Article | Year |
|---|---|
Induction therapy with high-dose fluconazole plus flucytosine for human immunodeficiency virus-uninfected cryptococcal meningitis patients: Feasible or not?
Topics: Antifungal Agents; Drug Therapy, Combination; Fluconazole; Flucytosine; HIV; HIV Infections; Humans; | 2023 |
Different presentations and outcomes between HIV-infected and HIV-uninfected patients with Cryptococcal meningitis.
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Amphotericin B; Antifungal Agents; Antigens, Fun | 2012 |
Synthesis, anti-human immunodeficiency virus and anti-hepatitis B virus activities of novel oxaselenolane nucleosides.
Topics: Anti-HIV Agents; Antiviral Agents; Cytosine; Flucytosine; Hepatitis B virus; HIV; Humans; Indicators | 1997 |
Stereospecific synthesis and biological evaluations of beta-L-pentofuranonucleoside derivatives of 5-fluorouracil and 5-fluorocytosine.
Topics: Animals; Anti-HIV Agents; Antineoplastic Agents; Cell Division; Drug Design; Flucytosine; Fluorourac | 2001 |